Loading market dashboard
Grifols, S.A.
GRFSHealthcareNASDAQES
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader with global scale and supply security advantages. GRFS trades at a significant valuation discount—forward P/E of 8.42x and price/cash flow of 4.76x—despite robust EBITDA, margin expansion, and improving free cash flow. Recent refinancing pushes major debt maturities to 2028; management guides for 2026 EBITDA margins of at least 25% and €500–€575 million free cash flow pre-dividends.
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
Aldeyra Therapeutics (NASDAQ: ALDX - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation. Volatility and Risk Aldeyra Therapeutics has a beta of
OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people who sold their plasma to the giant multinational. A third person is suing the hugely profitable Grifols for kidney damage from a plasma sale. Health Canada also reports non-compliance at four other Grifols sites.
Healthcare company Grifols said on Tuesday it has approved a U.S. initial public offering of its U.S. biopharma business.
BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today shared proof-of-concept data from its Chronos-PD program, demonstrating that biological changes in individuals with Parkinson's disease (PD) occur more than a decade before clinical diagnosis, with potential future implications for early detection and intervention.
TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press conference this morning to respond to a report from CBC about two patients who died in Winnipeg after having their blood plasma harvested at centres owned by for-profit pharmaceutical corporation Grifols. Another report followed, of a man who is suing , alleging kidney damage from equipment failure while having his plasma harvested at a Grifols centre. The Alberta Friends of Medicare revealed that Grifols has been found non-compliant with serious breaches at their Calgary centre. Inspection reports from Health Canada show that four Grifols centres have been found non-compliant in Calgary , Alberta; St. John , New Brunswick; and Regina and Saskatoon , Saskatchewan.
WINNIPEG, Manitoba and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- What: Spokespeople from the Manitoba Health Coalition and Ontario Health Coalition will respond to the sad news of two deaths of paid “donors” at for-profit plasma collection facilities owned by pharma giant Grifols. The Coalitions have long raised warnings about safety and the ownership and control of the blood system.
Grifols is a global leader in blood plasma, now rated 'BUY' with a €20/share PT and $23/share ADR target. GRFS has delivered €450M in cost savings, 150%+ net profit growth, and FCF exceeding guidance, with leverage down to 4.2x. Despite a BB- rating, improved fundamentals, dividend reinstatement, and forecasted 20–25% annual growth support a strong risk/reward profile.
